Maynard Um
-
-
-
-
-
-
-
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
-
-
-
-
-
-
-
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
-
-
-
-
-
-
-
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
-
-
-
419,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

